Original language | English |
---|---|
Pages (from-to) | 1411-1413 |
Number of pages | 3 |
Journal | Circulation |
Volume | 147 |
Issue number | 18 |
DOIs | |
Publication status | Published - 2 May 2023 |
Keywords
- adverse effects
- atherosclerosis
- data science
- hydroxymethylglutaryl-CoA reductase inhibitors
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Circulation, Vol. 147, No. 18, 02.05.2023, p. 1411-1413.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients with Atherosclerotic Cardiovascular Disease
AU - Virani, Salim S.
AU - Ramsey, David J.
AU - Westerman, Dax
AU - Kuebeler, Mark K.
AU - Chen, Liang
AU - Akeroyd, Julia M.
AU - Gobbel, Glenn T.
AU - Ballantyne, Christie M.
AU - Petersen, Laura A.
AU - Turchin, Alexander
AU - Matheny, Michael E.
N1 - Funding Information: Dr Virani is supported by research grants from the Department of Veterans Affairs, the National Institutes of Health (NIH), Tahir and Jooma Family; and has received honoraria from the American College of Cardiology in his role as associate editor for Innovations, ACC.org. Dr Turchin has received research support from Astra Zeneca, Eli Lilly, Novo Nordisk; consulting fees from Novo Nordisk, Proteomics International; and holds equity interest in Brio Systems. Dr Ballantyne has received grants/research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, American Heart Association, and Americans With Disabilities Act[AQ: Please confirm expansion of ADA in Disclosures.]; and consulting fees from 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, and Roche Diagnostic. Funding Information: This work was supported by a Department of Veterans Affairs (VA) Health Services Research & Development service investigator initiated grant (IIR 16-072) and a Houston VA Health Services Research & Development Center for Innovations grant (CIN13413). Support for VA/Centers for Medicare & Medicaid Services data was provided by the Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center.
PY - 2023/5/2
Y1 - 2023/5/2
KW - adverse effects
KW - atherosclerosis
KW - data science
KW - hydroxymethylglutaryl-CoA reductase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85153255867&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.123.064226
DO - 10.1161/CIRCULATIONAHA.123.064226
M3 - Article
C2 - 36871214
AN - SCOPUS:85153255867
SN - 0009-7322
VL - 147
SP - 1411
EP - 1413
JO - Circulation
JF - Circulation
IS - 18
ER -